偶发胰腺囊性病变:自然史回顾性分析及影像监测指南效能评估
单中心回顾性分析2012至2017年449例患者556个偶发胰腺囊性病变,自然增长速度为0.33 mm/年,恶性肿瘤发生率约2%;高风险征象与恶性相关而「显著增长」不相关;四大指南对恶性病变的敏感度仅33.3%至66.7%,仍漏诊1/3至2/3的癌症。
要点
- 偶发胰腺囊性病变自然增长约0.33 mm/年,可与ACR和CAR指南的显著增长阈值重叠。
- 高风险征象与恶性相关,而「显著增长」与恶性无关。
- 四大监测指南对恶性病变的敏感度仅33.3%至66.7%,漏诊1/3至2/3的癌症。
核心结论
- 偶发胰腺囊性病变常见、绝大多数为良性且生长缓慢;高风险征象的出现与恶性相关,而「显著增长」与恶性无关,因其可与自然生长重叠;尽管各指南推荐的随访时长和频率不同,监测指南仍漏诊1/3至2/3的癌症。
研究设计与样本
- 单中心回顾性分析,纳入2012年至2017年发现的偶发胰腺囊性病变,通过检索放射学报告关键词识别患者并人工复核排除随访不足5年、非偶发、已知胰腺癌或胰腺炎者,最终纳入449例患者(67±12岁,284例女性)共556个病变;回顾基线与随访影像记录大小、增长(按美国放射学会定义)、高风险征象及恶性发生率;回顾性应用国际共识、欧洲、ACR和加拿大放射科医师协会四大指南评估对浸润性病变的检出敏感度;良恶性结局比较采用Fisher精确检验,病变增长采用混合效应回归建模。
诊断标准与关键数值
- 胰腺癌发生率:9例患者在21,996患者年随访中发生胰腺癌(4.1例/10,000患者年);恶性与显著增长无关(4/9 vs 107/547,p=0.084),与高风险征象相关(3/9 vs 3/547,p<0.001);四大指南对恶性病变的敏感度范围为33.3%至66.7%(2-4/6例)。
临床应用与阅片要点
- 作者认为放射科医师和影像监测指南应考虑偶发胰腺囊性病变的自然生长;鉴于恶性率低、漏诊癌症比例高及过度治疗风险,影像监测指南的有效性仍不明确。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the natural history of incidental pancreatic cystic lesions (PCLs) and the sensitivity of surveillance guidelines to detect malignancy.
MATERIALS AND METHODS: We performed a single-center retrospective analysis of incidental PCLs discovered between 2012 and 2017. Patients were identified by searching radiology reports for relevant keywords, then search results were manually reviewed to exclude patients with < 5 years of follow-up, non-incidental PCLs, known pancreatic cancer, or pancreatitis. Baseline and follow-up imaging was reviewed to record size, growth (as defined by the American College of Radiology (ACR)), high-risk stigmata, and incidence of malignancy. Four major guidelines (International Consensus, European, ACR, and Canadian Association of Radiologists (CAR)) were retrospectively applied to assess sensitivity to detect invasive disease. Benign and malignant PCL outcomes were compared (Fisher's exact test), and PCL growth was modeled (mixed-effects regression).
RESULTS: Four hundred and forty-nine patients (67 ± 12 years, 284 women) with 556 PCLs were included. PCL natural growth was 0.33 mm/year (0.26-0.40 mm 95% CI), which overlaps with significant growth thresholds for ACR and CAR guidelines. Nine patients over 21,996 patient-years of follow-up developed pancreatic cancer (4.1 cases/10,000 patient-years). Malignancy was not associated with significant growth (4/9 vs 107/547, p = 0.084) but was with high-risk stigmata (3/9 vs 3/547, p < 0.001). Guideline sensitivities ranged from 33.3 to 66.7% (2-4/6 cases).
CONCLUSION: PCLs are common, overwhelmingly benign, and grow slowly. Development of high-risk stigmata is associated with malignancy but not "significant growth," which can overlap with natural PCL growth. Despite differences in recommended duration and frequency of follow-up, surveillance guidelines still miss 1/3-2/3 of cancers.
KEY POINTS: Question There is limited evidence on the natural growth and malignant potential of incidental pancreatic cystic lesions. Findings Incidental pancreatic cystic lesions grew slowly (0.3 mm/year) and were uncommonly malignant (2%). Retrospective application of surveillance guidelines missed 1/3-2/3 of cancers. Clinical relevance Radiologists and imaging surveillance guidelines should account for the natural growth of incidental pancreatic cystic lesions. Given the low rate of malignancy, high proportion of missed cancers, and risk of overtreatment, the effectiveness of imaging surveillance guidelines remains unclear.
引用
- Linehan V, Costa AF. Incidental pancreatic cystic lesions: retrospective analysis of natural history and efficacy of imaging surveillance guidelines. Eur Radiol. 2024. PMID: 39706924. doi:10.1007/s00330-024-11307-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。